从伦理和监管角度看病理学中的人工智能生成。

Brian R Jackson, Hooman H Rashidi, Jochen K Lennerz, M E de Baca
{"title":"从伦理和监管角度看病理学中的人工智能生成。","authors":"Brian R Jackson, Hooman H Rashidi, Jochen K Lennerz, M E de Baca","doi":"10.5858/arpa.2024-0205-RA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>Technology companies and research groups are increasingly exploring applications of generative artificial intelligence (GenAI) in pathology and laboratory medicine. Although GenAI holds considerable promise, it also introduces novel risks for patients, communities, professionals, and the scientific process.</p><p><strong>Objective.—: </strong>To summarize the current frameworks for the ethical development and management of GenAI within health care settings.</p><p><strong>Data sources.—: </strong>The analysis draws from scientific journals, organizational websites, and recent guidelines on artificial intelligence ethics and regulation.</p><p><strong>Conclusions.—: </strong>The literature on the ethical management of artificial intelligence in medicine is extensive but is still in its nascent stages because of the evolving nature of the technology. Effective and ethical integration of GenAI requires robust processes and shared accountability among technology vendors, health care organizations, regulatory bodies, medical professionals, and professional societies. As the technology continues to develop, a multifaceted ecosystem of safety mechanisms and ethical oversight is crucial to maximize benefits and mitigate risks.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ethical and Regulatory Perspectives on Generative Artificial Intelligence in Pathology.\",\"authors\":\"Brian R Jackson, Hooman H Rashidi, Jochen K Lennerz, M E de Baca\",\"doi\":\"10.5858/arpa.2024-0205-RA\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context.—: </strong>Technology companies and research groups are increasingly exploring applications of generative artificial intelligence (GenAI) in pathology and laboratory medicine. Although GenAI holds considerable promise, it also introduces novel risks for patients, communities, professionals, and the scientific process.</p><p><strong>Objective.—: </strong>To summarize the current frameworks for the ethical development and management of GenAI within health care settings.</p><p><strong>Data sources.—: </strong>The analysis draws from scientific journals, organizational websites, and recent guidelines on artificial intelligence ethics and regulation.</p><p><strong>Conclusions.—: </strong>The literature on the ethical management of artificial intelligence in medicine is extensive but is still in its nascent stages because of the evolving nature of the technology. Effective and ethical integration of GenAI requires robust processes and shared accountability among technology vendors, health care organizations, regulatory bodies, medical professionals, and professional societies. As the technology continues to develop, a multifaceted ecosystem of safety mechanisms and ethical oversight is crucial to maximize benefits and mitigate risks.</p>\",\"PeriodicalId\":93883,\"journal\":{\"name\":\"Archives of pathology & laboratory medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of pathology & laboratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5858/arpa.2024-0205-RA\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2024-0205-RA","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景技术公司和研究团体正在越来越多地探索生成式人工智能(GenAI)在病理学和实验室医学中的应用。尽管 GenAI 前景广阔,但它也给患者、社区、专业人员和科学进程带来了新的风险:总结当前在医疗保健环境中开发和管理 GenAI 的伦理框架:分析数据来自科学杂志、组织网站以及近期有关人工智能伦理和监管的指导方针:有关人工智能在医疗中的伦理管理的文献非常广泛,但由于该技术的不断发展,目前仍处于初级阶段。GenAI 的有效和伦理整合要求技术供应商、医疗机构、监管机构、医疗专业人员和专业协会之间建立健全的流程和共同的问责制。随着该技术的不断发展,一个由安全机制和道德监督组成的多层面生态系统对于实现效益最大化和降低风险至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ethical and Regulatory Perspectives on Generative Artificial Intelligence in Pathology.

Context.—: Technology companies and research groups are increasingly exploring applications of generative artificial intelligence (GenAI) in pathology and laboratory medicine. Although GenAI holds considerable promise, it also introduces novel risks for patients, communities, professionals, and the scientific process.

Objective.—: To summarize the current frameworks for the ethical development and management of GenAI within health care settings.

Data sources.—: The analysis draws from scientific journals, organizational websites, and recent guidelines on artificial intelligence ethics and regulation.

Conclusions.—: The literature on the ethical management of artificial intelligence in medicine is extensive but is still in its nascent stages because of the evolving nature of the technology. Effective and ethical integration of GenAI requires robust processes and shared accountability among technology vendors, health care organizations, regulatory bodies, medical professionals, and professional societies. As the technology continues to develop, a multifaceted ecosystem of safety mechanisms and ethical oversight is crucial to maximize benefits and mitigate risks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. Ethical and Regulatory Perspectives on Generative Artificial Intelligence in Pathology. Reduced Plasma Selenoprotein P Is Associated With Type I Antithrombin Deficiency and a Prothrombotic State. The Anatomic Pathology Hospitalist Model. Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1